Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Lincoln, Nebraska 68502


Purpose:

This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.


Criteria:

Inclusion Criteria: - Male or female between 18 to 55 years old - Male subjects must abstain from sexual intercourse or use a highly effective method of birth control - Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use a highly effective method of birth control - Body Mass Index (BMI) 18 to 32 kg/m2 - Willing and able to give informed consent - Additional inclusion criteria apply Exclusion Criteria: - Planning to conceive a child during the study or within 2 months after the last dose of study drug - Is positive for hepatitis A, B or C, and/or HIV - Has clinically significant abnormalities in baseline laboratory evaluations - Subject has a clinically significant abnormal electrocardiogram (ECG) - Participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to screening or is currently participating in another trial of an investigational drug (or medical device) - Additional exclusion criteria apply


NCT ID:

NCT03555617


Primary Contact:

Study Director
Nathan Pfiefer, PharmD, PhD
Theravance Biopharma


Backup Contact:

N/A


Location Contact:

Lincoln, Nebraska 68502
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.